HUTCHISON CHINA/S (NASDAQ:HCM) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Monday, BidAskClub reports.

Other analysts have also recently issued research reports about the company. Zacks Investment Research cut HUTCHISON CHINA/S from a “hold” rating to a “sell” rating in a research report on Tuesday, March 26th. HSBC began coverage on HUTCHISON CHINA/S in a research report on Wednesday, March 27th. They issued a “buy” rating for the company. Finally, Deutsche Bank began coverage on HUTCHISON CHINA/S in a research report on Monday, March 4th. They issued a “buy” rating and a $26.82 price target for the company. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $26.82.

Shares of HCM opened at $26.75 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.33 and a quick ratio of 4.19. The stock has a market capitalization of $3.56 billion, a price-to-earnings ratio of -46.93 and a beta of 1.04. HUTCHISON CHINA/S has a 52 week low of $20.83 and a 52 week high of $39.68.

Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its position in shares of HUTCHISON CHINA/S by 375.0% during the third quarter. Renaissance Technologies LLC now owns 32,300 shares of the company’s stock worth $1,040,000 after purchasing an additional 25,500 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of HUTCHISON CHINA/S by 748.9% during the first quarter. PNC Financial Services Group Inc. now owns 1,146 shares of the company’s stock worth $36,000 after purchasing an additional 1,011 shares in the last quarter. Deutsche Bank AG grew its position in shares of HUTCHISON CHINA/S by 300.9% during the fourth quarter. Deutsche Bank AG now owns 129,822 shares of the company’s stock worth $2,995,000 after purchasing an additional 97,440 shares in the last quarter. Baillie Gifford & Co. grew its position in shares of HUTCHISON CHINA/S by 0.6% during the fourth quarter. Baillie Gifford & Co. now owns 198,959 shares of the company’s stock worth $4,594,000 after purchasing an additional 1,213 shares in the last quarter. Finally, Barclays PLC purchased a new stake in shares of HUTCHISON CHINA/S during the fourth quarter worth about $807,000. Hedge funds and other institutional investors own 17.92% of the company’s stock.

About HUTCHISON CHINA/S

Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.

Further Reading: Overbought

Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.